Macular oedema treatment to be available on PBS

A government subsidy for a biologic to treat vision impairment caused by macular oedema in patients with diabetes or retinal vein occlusion (branch or central) will be available from 1 July. Professor Paul Mitchell, Head of Ophthalmology at Sydney’s Westmead Hospital welcomed the listing of Lucentis (ranibizumab) on the PBS for patients experiencing vision loss